Literature DB >> 6766799

Treatment of cultured human colon carcinoma cells with fluorinated pyrimidines.

B Drewinko, L Y Yang, D H Ho, J Benvenuto, T L Loo, E J Freireich.   

Abstract

The shape of the initial part of the dose-dependent response curve of LoVo cells, an established human colon carcinoma cell line, exposed for 1 hr to graded concentrations of 5-FU depended on the medium supplement, i.e., fetal calf serum (FCS), in which the cells were treated and subsequently incubated for colony-formation. At concentrations of 50--100 micrograms/ml (equivalent to peak plasma levels following an in vivo bolus dose of 15 mg/kg) cell kill was completely prevented by FCS. The serum did not contain thymidine (TdR) but had significant amounts of uridine (UR). When 5-FU was delivered in dialyzed FCS, concentrations of 50--100 micrograms/ml achieved only a modest 15% cell kill after 1 hour treatment. Regardless of medium supplement, the killing effect of 5-FU did not increase beyond concentrations greater than 2,000 micrograms/ml. Increasing the exposure interval dramatically increased the killing of LoVo cells by 5-FU, although the effects of medium supplement on the degree of cell survival persisted for about 12 hours. Virtually all of the incorporated 5-FU was transformed into 5-FUR, and a very small proportion eventually was incorporated into nucleic acids, suggesting that the killing effect of 5-FU on LoVo cells is mediated mostly by ribosidation and not by conversion into the deoxyribonucleoside. This conclusion is supported by the failure of 5-FUdR to kill LoVo cells after a treatment interval of one hour, even at concentrations of 5000 micrograms/ml; yet after the same exposure interval, 5-FUR effectively killed cells at concentrations of 50--100 micrograms/ml. TdR afforded no protection from cell kill by 5-FU. In contrast, UR was capable of protecting LoVo cells from the lethal effects of both 5-FU and 5-FUR even at concentrations as low as 10 micrograms/ml. Ftorafur exposed to LoVo cells for 1 hour had a slight killing effect (about 20--25%) at concentrations ranging up to 2000 micrograms/ml. Although the lethal effect of ftorafur was slightly increased after longer periods of incubation, it failed to reach 90% even after intervals of 48 hours. The results on cellular sensitivity that we obtained for LoVo cells treated with various fluorinated pyrimidines differ substantially from those of other investigators who used different methods to assess cell killing on nonhuman and noncolonic cell systems. The predictive relevance of these data as compared to those obtained in other systems is justified by the suboptimal results with these agents in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6766799     DOI: 10.1002/1097-0142(19800315)45:5+<1144::aid-cncr2820451319>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Continuous infusion of chemotherapy: focus on 5-fluorouracil and fluorodeoxyuridine.

Authors:  R L Poorter; P J Bakker; C H Veenhof
Journal:  Pharm World Sci       Date:  1998-04

2.  Concentration and time dependence of the toxicity of fluorinated pyrimidines to HT 29 colorectal carcinoma cells.

Authors:  K H Link; K R Aigner; K Peschau; M Warthona; K Schwemmle; P V Danenberg
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 3.  Cancer of the esophagus: the Wayne State University experience.

Authors:  L Leichman
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

4.  Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel.

Authors:  Hee Yi; Hee-Jung Cho; Soo-Min Cho; Dong-Goo Lee; A M Abd El-Aty; So-Jeong Yoon; Gun-Won Bae; Kwang Nho; Bokyung Kim; Chi-Ho Lee; Jin-Suk Kim; Michael G Bartlett; Ho-Chul Shin
Journal:  BMC Cancer       Date:  2010-05-18       Impact factor: 4.430

5.  Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.

Authors:  Jonathan R Brody; Tomas Hucl; Christina L Costantino; James R Eshleman; Eike Gallmeier; Heng Zhu; Michiel S van der Heijden; Jordan M Winter; Agnieszka K Wikiewicz; Charles J Yeo; Scott E Kern
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701

6.  Phase II trial of intravenous melphalan in advanced colorectal carcinoma.

Authors:  D F Moore; R Pazdur; J L Abbruzzese
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

7.  Kinetic analysis of 5-fluorouracil action against various cancer cells.

Authors:  M Inaba; J Mitsuhashi; S Ozawa
Journal:  Jpn J Cancer Res       Date:  1990-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.